ANCA Screen Test

An ANCA screen looks for autoantibodies that target proteins inside neutrophils, a type of white blood cell involved in frontline immune defense. Autoantibodies are antibodies that mistakenly target the body’s own tissues. In this test the target is the cytoplasmic compartment of neutrophils, meaning the internal space of the cell that holds enzymes used for pathogen killing. When these autoantibodies appear they can activate neutrophils in a way that causes inflammation in blood vessel walls. This can lead to vasculitis, which means inflammation and injury of blood vessels. The resulting damage can affect organs such as the kidneys, lungs, skin, and peripheral nerves.

The screen usually begins with a technique called indirect immunofluorescence. This method uses ethanol fixed neutrophils placed on a slide. When a patient’s serum is added ANCA antibodies bind to specific proteins within these cells. A fluorescent marker then highlights the binding pattern under a microscope. Two main patterns help guide interpretation. A cytoplasmic pattern forms when antibodies bind throughout the neutrophil interior and usually reflects antibodies against an enzyme called proteinase 3. A perinuclear pattern forms when antibodies cluster around the nucleus and usually reflects antibodies against another enzyme called myeloperoxidase. These enzymes normally help neutrophils kill microbes, and their names often appear in more advanced discussions of vasculitis. After the initial pattern is identified, confirmatory immunoassays determine whether the antibodies target proteinase 3 or myeloperoxidase. These antigen specific results carry greater specificity for the major forms of ANCA associated vasculitis.

When ANCA levels are high they can point toward conditions such as granulomatosis with polyangiitis or microscopic polyangiitis. These illnesses often involve kidney inflammation, lung nodules, sinus disease, or nerve injury. Low level positivity can sometimes occur in autoimmune liver disease, inflammatory bowel disease, infections, or drug reactions. A positive ANCA screen alone cannot diagnose vasculitis. Some patients with clinically significant vasculitis will have negative tests which is often called seronegative disease. False positives also occur because the antibodies may appear in people who do not have inflammatory injury to blood vessels. Clinicians therefore interpret results alongside symptoms, imaging, kidney function, and tissue biopsy when needed.

A normal or negative ANCA screen does not rule out disease, especially in early stages. A positive screen without supportive clinical findings rarely indicates true vasculitis. The value of the test lies in how well the results fit the broader clinical picture rather than in isolation.